55 breast carcinomas and 9 its benign conditions were studied immunohistochemically. Oncoprotein c-erbB-2 was found in 22% carcinomas and in 33-37% comedo-carcinomas. Coincidence of predominant expression of oncoprotein c-erbB-2 and tenascin was observed. Maximal damage of the basal membrane in the intraductal carcinoma detected by the disturbance of type IV collagen staining was observed in cases of the highest expression of oncoprotein c-erbB-2 and tenascin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
[Cardiotoxicity from anti-HER-2 therapies in patients with HER-2 positive breast cancer].
Rev Med Inst Mex Seguro Soc
January 2024
Universidad de la República, Facultad de Medicina, Servicio de Oncología Clínica. Montevideo, Uruguay.
Background: HER-2 positive (+) breast cancer (BC) accounts for 20-25% of BC, it is more aggressive, and it has a lower survival rate. Since the approval of trastuzumab in 1998, other HER-2-targeted therapies such as pertuzumab and trastuzumab emtansine (TDM1) have been introduced, improving patient survival. However, cardiotoxicity is an adverse effect of these treatments.
View Article and Find Full Text PDFTumor Markers and Their Prognostic Value in Sinonasal ITAC/Non-ITAC.
Cancers (Basel)
June 2023
Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands.
One of the rare tumor entities present in the nose and paranasal sinuses is sinonasal (non-) intestinal-type adenocarcinoma (ITAC/non-ITAC). Currently, surgery with postoperative radiotherapy is the cornerstone of the treatment of these tumors. Systemic treatment is usually applied in a palliative setting.
View Article and Find Full Text PDFIn this work, a novel design of ArcTFET based on Charge-Plasma and Gate-Stack (CP-GS-ArcTFET) is proposed for the first time. The precise detection of breast cancer biomarker (C-erbB-2) through serum should not be limited by HEMT devices but should be explored with other novel devices also. In this regard, investigation in above-mentioned device is carried out for the detection of C-erbB-2 protein.
View Article and Find Full Text PDFCMBs carrying PTX and CRISPR/Cas9 targeting plasmids interfere with endometrial cancer cells.
Mol Med Rep
December 2021
Department of Gynaecology and Obstetrics, Hainan General Hospital/Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan 570311, P.R. China.
Development of combination therapy to decrease side effects of chemotherapeutic drugs and increase their utilization rate in combination with gene editing is a key research topic in tumor treatment. The present study aimed to investigate the effect of cationic microbubbles (CMBs) carrying paclitaxel (PTX) and knockout plasmid on the endometrial cancer cell line HEC‑1A and to determine how regulates the function of endometrial cancer cells. Cells were treated with CMB, PTX, PTX‑CMBs, cationic plasmid‑carrying or cationic PTX‑carrying plasmid groups.
View Article and Find Full Text PDFImmunohistochemical and Morphological Features of Bovine Granulosa Cell Tumours in Relation to Growth Pattern and Folliculogenesis.
J Comp Pathol
August 2021
Department of Veterinary Pathology. Electronic address:
Granulosa cell tumours (GCTs) are the most common type of bovine ovarian neoplasm. We describe the morphological and immunohistochemical features of GCTs (n = 26) and a thecoma (n = 1) using antibodies to cytokeratin AE1/AE3, vimentin, desmin, nectin-4, anti-Müllerian hormone (AMH), inhibin α, c-erbB-2 oncoprotein and proliferating cell nuclear antigen. The results indicate that, based on the expression similarity of AE1/AE3 and inhibin α, the macrofollicular growth pattern of GCTs derives from highly differentiated granulosa cells (GCs), the Graafian follicle or early atretic follicle.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!